reading 503A threads from 2024 and half of it aged badly
Something I keep coming back to: reading 503A threads from 2024 and half of it aged badly.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Careful.
hassan_chowdhury is right about the concentration trap. It breaks arithmetic that has been reliable for months.
hassan_chowdhury is right about the concentration trap.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
the label on a compounded vial is a legal document, read it
ask which facility, then ask for their testing
a telehealth intake that asks nothing has told you what it is
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
do not assume the concentration matches the branded product
- 1Asked for the beyond-use date basis and got a real answer with a stability…13 comments in this branch · started by u/swirl_dont_shake